Cargando…
Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2
The severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) has resulted in almost 28 million cases of COVID-19 (Corona virus disease-2019) and more than 900000 deaths worldwide since December 2019. In the absence of effective antiviral therapy and vaccine, treatment of COVID-19 is largely sym...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485553/ https://www.ncbi.nlm.nih.gov/pubmed/32926917 http://dx.doi.org/10.1016/j.ejphar.2020.173545 |
_version_ | 1783581173389197312 |
---|---|
author | Kaur, Upinder Acharya, Kumudini Mondal, Ritwick Singh, Amit Saso, Luciano Chakrabarti, Sasanka Chakrabarti, Sankha Shubhra |
author_facet | Kaur, Upinder Acharya, Kumudini Mondal, Ritwick Singh, Amit Saso, Luciano Chakrabarti, Sasanka Chakrabarti, Sankha Shubhra |
author_sort | Kaur, Upinder |
collection | PubMed |
description | The severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) has resulted in almost 28 million cases of COVID-19 (Corona virus disease-2019) and more than 900000 deaths worldwide since December 2019. In the absence of effective antiviral therapy and vaccine, treatment of COVID-19 is largely symptomatic. By making use of its spike (S) protein, the virus binds to its primary human cell receptor, angiotensin converting enzyme 2 (ACE2) which is present in the pulmonary epithelial cells as well as other organs. SARS-CoV-2 may cause a downregulation of ACE2. ACE2 plays a protective role in the pulmonary system through its Mas-receptor and alamandine-MrgD-TGR7 pathways. Loss of this protective effect could be a major component of COVID-19 pathogenesis. An attractive strategy in SARS-CoV-2 therapeutics would be to augment ACE2 either directly by supplementation or indirectly through drugs which increase its levels or stimulate its downstream players. In this semi-systematic review, we have analysed the pathophysiological interplay between ACE and ACE2 in the cardiopulmonary system, the modulation of these two proteins by SARS-CoV-2, and potential therapeutic avenues targeting ACE-Ang II and ACE2-Ang (1–7) axes, that can be utilized against COVID-19 disease progression. |
format | Online Article Text |
id | pubmed-7485553 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74855532020-09-14 Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2 Kaur, Upinder Acharya, Kumudini Mondal, Ritwick Singh, Amit Saso, Luciano Chakrabarti, Sasanka Chakrabarti, Sankha Shubhra Eur J Pharmacol Full Length Article The severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) has resulted in almost 28 million cases of COVID-19 (Corona virus disease-2019) and more than 900000 deaths worldwide since December 2019. In the absence of effective antiviral therapy and vaccine, treatment of COVID-19 is largely symptomatic. By making use of its spike (S) protein, the virus binds to its primary human cell receptor, angiotensin converting enzyme 2 (ACE2) which is present in the pulmonary epithelial cells as well as other organs. SARS-CoV-2 may cause a downregulation of ACE2. ACE2 plays a protective role in the pulmonary system through its Mas-receptor and alamandine-MrgD-TGR7 pathways. Loss of this protective effect could be a major component of COVID-19 pathogenesis. An attractive strategy in SARS-CoV-2 therapeutics would be to augment ACE2 either directly by supplementation or indirectly through drugs which increase its levels or stimulate its downstream players. In this semi-systematic review, we have analysed the pathophysiological interplay between ACE and ACE2 in the cardiopulmonary system, the modulation of these two proteins by SARS-CoV-2, and potential therapeutic avenues targeting ACE-Ang II and ACE2-Ang (1–7) axes, that can be utilized against COVID-19 disease progression. Elsevier B.V. 2020-11-15 2020-09-11 /pmc/articles/PMC7485553/ /pubmed/32926917 http://dx.doi.org/10.1016/j.ejphar.2020.173545 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Full Length Article Kaur, Upinder Acharya, Kumudini Mondal, Ritwick Singh, Amit Saso, Luciano Chakrabarti, Sasanka Chakrabarti, Sankha Shubhra Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2 |
title | Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2 |
title_full | Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2 |
title_fullStr | Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2 |
title_full_unstemmed | Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2 |
title_short | Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2 |
title_sort | should ace2 be given a chance in covid-19 therapeutics: a semi-systematic review of strategies enhancing ace2 |
topic | Full Length Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485553/ https://www.ncbi.nlm.nih.gov/pubmed/32926917 http://dx.doi.org/10.1016/j.ejphar.2020.173545 |
work_keys_str_mv | AT kaurupinder shouldace2begivenachanceincovid19therapeuticsasemisystematicreviewofstrategiesenhancingace2 AT acharyakumudini shouldace2begivenachanceincovid19therapeuticsasemisystematicreviewofstrategiesenhancingace2 AT mondalritwick shouldace2begivenachanceincovid19therapeuticsasemisystematicreviewofstrategiesenhancingace2 AT singhamit shouldace2begivenachanceincovid19therapeuticsasemisystematicreviewofstrategiesenhancingace2 AT sasoluciano shouldace2begivenachanceincovid19therapeuticsasemisystematicreviewofstrategiesenhancingace2 AT chakrabartisasanka shouldace2begivenachanceincovid19therapeuticsasemisystematicreviewofstrategiesenhancingace2 AT chakrabartisankhashubhra shouldace2begivenachanceincovid19therapeuticsasemisystematicreviewofstrategiesenhancingace2 |